Literature DB >> 23385745

The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS.

D X Beringer1, L M J Kroon-Batenburg.   

Abstract

Coagulation factor XII (FXII) is a key protein in the intrinsic coagulation and kallikrein-kinin pathways. It has been found that negative surfaces and amyloids, such as Aβ fibrils, can activate FXII. Additionally, it has been suggested that FXII simulates cells and that it plays an important role in thrombosis. To date, no structural data on FXII have been deposited, which makes it difficult to support any hypothesis on the mechanism of FXII function. The crystal structure of the FnI-EGF-like tandem domain of FXII presented here was solved using experimental phases. To determine the phases, a SIRAS approach was used with a native and a holmium chloride-soaked data set. The holmium cluster was coordinated by the C-terminal tails of two symmetry-related molecules. Another observation was that the FnI domain was much more ordered than the EGF-like domain owing to crystal packing. Furthermore, the structure shows the same domain orientation as the homologous FnI-EGF-like tandem domain of tPA. The plausibility of several proposed interactions of these domains of FXII is discussed. Based on this FXII FnI-EGF-like structure, it could be possible that FXII binding to amyloid and negatively charged surfaces is mediated via this part of FXII.

Entities:  

Keywords:  EGF-like domain; FXII; Hageman factor; experimental phasing; fibronectin type I domain

Mesh:

Substances:

Year:  2013        PMID: 23385745      PMCID: PMC3564606          DOI: 10.1107/S1744309113000286

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  47 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Autoactivation of human blood coagulation factor XII on dextran derivatives of different molecular weight.

Authors:  S Tazi; G Tans; H C Hemker; J M Nigretto
Journal:  Thromb Res       Date:  1992-09-15       Impact factor: 3.944

3.  Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase.

Authors:  P M Jansen; R A Pixley; M Brouwer; I W de Jong; A C Chang; C E Hack; F B Taylor; R W Colman
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

4.  Mapping of a putative surface-binding site of human coagulation factor XII.

Authors:  B J Clarke; H C Côté; D E Cool; I Clark-Lewis; H Saito; R A Pixley; R W Colman; R T MacGillivray
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

5.  Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa.

Authors:  D E Cool; C J Edgell; G V Louie; M J Zoller; G D Brayer; R T MacGillivray
Journal:  J Biol Chem       Date:  1985-11-05       Impact factor: 5.157

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Critical functional requirement for the guanidinium group of the arginine 41 side chain of human epidermal growth factor as revealed by mutagenic inactivation and chemical reactivation.

Authors:  D A Engler; S R Campion; M R Hauser; J S Cook; S K Niyogi
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

8.  Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs.

Authors:  Coen Maas; Bettina Schiks; Remo D Strangi; Tilman M Hackeng; Bonno N Bouma; Martijn F B G Gebbink; Barend Bouma
Journal:  Amyloid       Date:  2008-09       Impact factor: 7.141

9.  Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.

Authors:  Coen Maas; José W P Govers-Riemslag; Barend Bouma; Bettina Schiks; Bouke P C Hazenberg; Henk M Lokhorst; Per Hammarström; Hugo ten Cate; Philip G de Groot; Bonno N Bouma; Martijn F B G Gebbink
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

10.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

View more
  5 in total

1.  A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation.

Authors:  Zonne L M Hofman; Chantal C Clark; Wariya Sanrattana; Aziz Nosairi; Naomi M J Parr; Minka Živkovic; Karoline Krause; Niklas A Mahnke; Jörg Scheffel; C Erik Hack; Marcus Maurer; Steven de Maat; Coen Maas
Journal:  J Biol Chem       Date:  2019-11-26       Impact factor: 5.157

2.  Heparan sulfate proteoglycans mediate factor XIIa binding to the cell surface.

Authors:  Lukasz Wujak; Miroslava Didiasova; Dariusz Zakrzewicz; Helena Frey; Liliana Schaefer; Malgorzata Wygrecka
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

3.  Modeling and dynamical analysis of the full-length structure of factor XII with zinc.

Authors:  Evren Kılınç; Ahmet Can Timucin; Suleyman Selim Cinaroglu; Emel Timucin
Journal:  J Mol Model       Date:  2022-04-25       Impact factor: 1.810

4.  Coagulation factor XII protease domain crystal structure.

Authors:  M Pathak; P Wilmann; J Awford; C Li; B K Hamad; P M Fischer; I Dreveny; L V Dekker; J Emsley
Journal:  J Thromb Haemost       Date:  2015-03-11       Impact factor: 5.824

5.  Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains.

Authors:  Aleksandr Shamanaev; Ivan Ivanov; Mao-Fu Sun; Maxim Litvak; Priyanka Srivastava; Bassem M Mohammed; Rabia Shaban; Ashoka Maddur; Ingrid M Verhamme; Owen J T McCarty; Ruby H P Law; David Gailani
Journal:  Blood Adv       Date:  2022-05-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.